Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $7.70 | N/A | -14.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $7.70 | N/A | -14.01% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market environment. They highlighted the need for strategic adjustments moving forward.
Management acknowledged challenges in meeting market expectations.
They emphasized ongoing efforts to enhance production capabilities.
This earnings report indicates that Moderna's performance fell short of expectations, particularly in EPS. The stock reacted negatively, dropping nearly 18%, likely due to investor concerns over the company's ability to meet future earnings targets and the lack of guidance. The management's defensive tone suggests they are aware of the challenges ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021